Homeovitality Endocare

Endocare has been developed to suppress endothelial cell mediated chronic inflammation by targeting the SIRT6 gene.

What does SIRT6 do?

Chronic inflammation predisposes to development of many serious diseases.

There are a number of ways in which inflammation can be mediated. It can be brought about by excessive immune responsiveness. This type of inflammation can be controlled by promoting the production of the immune suppressant, IL-10. This forms the basis of the Allergicare Micro-DNA therapy preparation.

Chronic inflammation may also be driven by dysfunctional epithelial cells.

Endothelial cells (the endothelium) line the inner surface of the vessels of the blood system, including arteries, veins and capillaries and the lymphatic system. The endothelium plays a very important role on controlling optimum passage of many substances such as hormones and immune cells into surrounding tissues, as needed. When the function of endothelial cells is impaired, they release a range of pro-inflammatory substances that cause great damage to themselves and surrounding tissues. The result of endothelial damage leads to development of many disorders associated with local and systemic inflammation such as heart disease, atherosclerosis, diabetes, rheumatoid arthritis, abnormal growth of blood vessels (angiogenesis), cancer and rapid ageing [1, 2 & 3].

The release of inflammatory mediators from dysfunctional endothelial cells has been shown to be controlled by the recently discovered histone deacetylase SIRT6. Studies have shown that decreased expression of SIRT6 in endothelial cells leads to serious chronic inflammation. Inflammation resulting from dysfunctional endothelial cells is reduced when SIRT6 activity is increased, for review see Ref. 4.

References